NDA Receipt Total Of 116 In 2005 Affirms Modest Growth Since Millennium
This article was originally published in Pharmaceutical Approvals Monthly
The total of 116 NDAs received by CDER in calendar year 2005 continues a trend of modest growth since a user fee-era low of 98 NDAs received in 2001, according to statistics recently released by FDA
You may also be interested in...
FDA clearance of Bayer/Onyx’ Nexavar oncologic Dec. 20, ahead of its Jan. 11, 2006 user fee goal date, helped the agency achieve a total of 18 new molecular entity approvals in 2005.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011